CYP2E1 Rsa I/Pst I polymorphism is associated with lung cancer risk among Asians

Lung Cancer

Volumn 69, Issue 1, 2010, Pages 19-25

  Zhan, Ping ^a   Wang, Jing ^b   Zhang, Yu ^a   Qiu, Li Xin ^c   Zhao, Su feng ^d   Qian, Qian ^d   Wei, Shu Zhen ^d   Yu, Li Ke ^a   Song, Yong ^d  

^a NANJING CHEST HOSPITAL   (China)

^b THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^c FUDAN UNIVERSITY   (China)

^d MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

CYP2E1; Lung cancer; Meta analysis; Molecular epidemiology; Polymorphism; Susceptibility

Indexed keywords

CYTOCHROME P450 2E1;

ARTICLE; ASIAN; CANCER RISK; CANCER SUSCEPTIBILITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MOLECULAR EPIDEMIOLOGY; PRIORITY JOURNAL; SMOKING; ALLELE; ASIAN CONTINENTAL ANCESTRY GROUP; CAUCASIAN; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; LUNG NEOPLASMS; META ANALYSIS; RISK FACTOR;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2E1; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LUNG NEOPLASMS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 77953356395     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.09.001     Document Type: Article

References (52)

1. Alberg A.J., Samet J.M. Epidemiology of lung cancer. Chest 2003, 123:21-49.
2. Molina J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83:584-594.
3. Toh C.K., Gao F., Lim W.T., Leong S.S., Fong K.W., Yap S.P., et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 2006, 24:2245-2251.
4. Le Marchand L., Guo C., Benhamou S., Bouchardy C., Cascorbi I., Clapper M.L., et al. Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). Cancer Causes Control 2003, 14:339-346.
5. Carlsten C., Sagoo G.S., Frodsham A.J., Burke W., Higgins J.P. Glutathione S-transferase M1 (GSTM1) polymorphisms and lung cancer: a literature-based systematic HuGE review and meta-analysis. Am J Epidemiol 2008, 167:759-774.
6. Raimondi S., Paracchini V., Autrup H. Meta- and pooled analysis of GSTT1 and lung cancer: a HuGE-GSEC review. Am J Epidemiol 2006, 164:1027-1042.
7. Yamazaki H., Inui Y., Yun C., Guengerich F.P., Shimada T. Cytochrome P4502E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 1992, 13:1789-1794.
8. Bellec G., Dreano Y., Lozach P., Menez J.F., Berthou F. Cytochrome P450 metabolic dealkylation of nine N-nitroso-dialkylamines by human liver microsomes. Carcinogenesis 1996, 17:2029-2034.
9. Hoffmann D., Hecht S.S. Nicotine-derived N-nitrosamines and tobacco-related cancer: current status and future directions. Cancer Res 1985, 45:935-944.
10. Hecht S.S., Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis 1988, 9:875-884.
11. Uematsu F., Kikuchi H., Motomiya M., Abe T., Sagami I., Ohmachi T., et al. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn J Cancer Res 1991, 82:254-256.
12. Cochran W.G. The combination of estimates from different experiments. Biometrics 1954, 10:101-129.
13. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22:719-748.
14. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
15. Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Technol Bull 1999, 8:15-17.
16. Egger M., Davey Smith G., Schneider M., Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
17. Wu X., Amos C.I., Kemp B.L., Shi H., Jiang H., Wan Y., et al. Cytochrome P450 2E1 DraI polymorphisms in lung cancer in minority populations. Cancer Epidemiol Biomarkers Prev 1998, 7:13-18.
18. Gu Y.F., Zhang S.C., Lai B.T., Wang H., Zhan X.P. Relationship between genetic polymorphism of metabolizing enzymes and lung cancer susceptibility. Chin J Lung Cancer 2004, 7:112-117. [in Chinese].
19. Wang B.G., Chen S.D., Chen Y., Zhou W.P., Zeng M., Li Z.B. Case control study on impact of cytochrome P450 2E1 and 1A1 gene polymorphisms on the risk of lung cancer. Chin J Cancer Prev Treat 2004, 11:681-702. [in Chinese].
20. Li D.R., Zhou Q.H., Yuan T.Z., Guo Z.L., Zhu W., Wang Y.P., et al. Study on the association between genetic polymorphism of CYP2E1, GSTM1 and susceptibility of lung cancer. Chin J Lung Cancer 2005, 8:14-19. [in Chinese].
21. Eom S.Y., Zhang Y.W., Kim S.H., Choe K.H., Lee K.Y., Park J.D., et al. Influence of NQO1, ALDH2, and CYP2E1 genetic polymorphisms, smoking, and alcohol drinking on the risk of lung cancer in Koreans. Cancer Causes Control 2009, 20:137-145.
22. Zienolddiny S., Campa D., Lind H., Ryberg D., Skaug V., Stangeland L.B., et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis 2008, 29:1164-1169.
23. Li D., Zhou Q.H., Guo Z., Yuan T.Z., Zhu W., Wang Y.P., et al. Association between genetic polymorphisms of CYP2E1 and lung cancer susceptibility: a case control study. Acta Acdaemiae Medicine Militrais Tertiae 2008, 30:1231-1234. [in Chinese].
24. Minegishi Y., Tsukino H., Muto M., Goto K., Gemma A., Tsugane S., et al. Susceptibility to lung cancer and genetic polymorphisms in the alcohol metabolite-related enzymes alcohol dehydrogenase 3, aldehyde dehydrogenase 2, and cytochrome P450 2E1 in the Japanese population. Cancer 2007, 110:353-362.
25. Gu Y.F., Zhang Z.D., Zhang S.C., Zheng S.H., Jia H.Y., Gu S.X. Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility. Zhonghua Yi Xue Za Zhi 2007, 87:3064-3068. [in Chinese].
26. Ye W.Y., Chen S.D., Chen Q., Zhang D.Q., Cai X.L. Association of CYP2E1 polymorphism and serum selenium level with risk of human lung cancer. Tumor 2006, 26:450-452. [in Chinese].
27. Wang D.Q., Chen S.D., Wang B.G., Zhou W.P. A case-control study on the impact of cytochrome P450 2E1 and 1A1 gene polymorphisms on the risk of lung cancer of the Han nationality in Guangzhou district. Chin J Lung Cancer 2006, 9:497-501. [in Chinese].
28. Lee K.M., Kang D., Lee S.J., Park S.K., Lee K.H., Choi J.Y., et al. Interactive effect of genetic polymorphism of glutathione S-transferase M1 and smoking on squamous cell lung cancer risk in Korea. Oncol Rep 2006, 16:1035-1039.
29. Liang G.Y., Pu Y.P., Yin L.H. Studies of the genes related to lung cancer susceptibility in Nanjing Han population, China. Yi Chuan 2004, 26:584-588. [in Chinese].
30. Wang J., Deng Y., Li L., Kuriki K., Ding J., Pan X., et al. Association of GSTM1, CYP1A1 and CYP2E1 genetic polymorphisms with susceptibility to lung adenocarcinoma: a case-control study in Chinese population. Cancer Sci 2003, 94:448-452.
31. Shi Y., Zhou X., Zhou Y., Ren S. Analysis of CYP2E1, GSTM1 genetic polymorphisms in relation to human lung cancer and esophageal carcinoma [in Chinese]. J Huazhong Univ Sci Technol [Health Sci] 2002, 3:14-17.
32. Quiñones L., Lucas D., Godoy J., Cáceres D., Berthou F., Varela N., et al. CYP1A1, CYP2E1 and GSTM1 genetic polymorphisms. The effect of single and combined genotypes on lung cancer susceptibility in Chilean people. Cancer Lett 2001, 174:35-44.
33. Li Z., Tan W., Shao K. Susceptibility to lung cancer in Chinese is associated with genetic polymorphism in cytochrome P4502E1. Zhonghua Zhong Liu Za Zhi 2000, 22:5-7. [in Chinese].
34. Huang Y.H., Wang Q.S., Zhu L.Z., Zhang Y. Relationship between Cytochrome P450 2E1 genetic polymorphism and lung cancer in Chinese Han subjects. Chin J Clin Pharmacol 2000, 16:350-352. [in Chinese].
35. Wang S.L., Lee H., Chen K.W., Tsai K.J., Chen C.Y., Lin P. Cytochrome P4502E1 genetic polymorphisms and lung cancer in a Taiwanese population. Lung Cancer 1999, 26:27-34.
36. Le Marchand L., Sivaraman L., Pierce L., Seifried A., Lum A., Wilkens L.R., et al. Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res 1998, 58:4858-4863.
37. Qu Y.H., Shi Y.B., Zhong L.J., Sun L., Sun X.W., Chen J.R., et al. Cytochrome P450 2E1 genetic polymorphism and non-smoking female lung cancer risk. Carcinogenesis Teratogenesis Mutagenesis 1998, 10:355-358. [in Chinese].
38. Wu X., Shi H., Jiang H., Kemp B., Hong W.K., Delclos G.L., et al. Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis 1997, 18:967-973.
39. Oyama T., Kawamoto T., Mizoue T., Sugio K., Kodama Y., Mitsudomi T., et al. Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Anticancer Res 1997, 17:583-587.
40. Watanabe J., Yang J.P., Eguchi H., Hayashi S., Imai K., Nakachi K., et al. An Rsa I polymorphism in the CYP2E1 gene does not affect lung cancer risk in a Japanese population. Jpn J Cancer Res 1995, 86:245-248.
41. Persson I., Johansson I., Bergling H., Dahl M.L., Seidegård J., Rylander R., et al. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett 1993, 319:207-211.
42. Burg J.R., Gist G.L. The national exposure registry: procedures for establishing a registry of persons environmental exposed to hazardous substances. Toxicol Ind Health 1995, 11:231-248.
43. Shen X., Eang G., Huang Y., Xiang L., Wang X. Analysis and estimates of attributable risk factors for lung cancer in Nanjing, China. Lung Cancer (Suppl.) 1996, 14:S107-S112.
44. Gonzalez F.J., Gelboin H.V. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 1994, 26:165-183.
45. Windmill K.F., McKinnon R.A., Zhu X., Gaedigk, Grant D.M., McManus M.E. The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat Res 1997, 376:153-160.
46. Oyama T., Sugio K., Uramoto H., Kawamoto T., Kagawa N., Nadaf S., et al. Cytochrome P450 expression (CYP) in non-small cell lung cancer. Front Biosci 2007, 12:2299-2308.
47. Hirschhorn J.N., Lohmueller K., Byrne E. A comprehensive reviewof genetic association studies. Genet Med 2002, 4:45-61.
48. Sato S., Nakamura Y., Tsuchiya E. Difference of allelotype between squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res 1994, 54:5652-5655.
49. Hayashi S.I., Watanabe J., Kawajiri K. Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 1991, 110:559-565.
50. Lucas D., Menez C., Girre C., Berthou F., Bodenez P., Joannet I., et al. Cytochrome P4502E1 genotype and chloroxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics 1995, 5:298-304.
51. Kim R.B., Yamazaki H., Chiba K., O'Shea D., Mimura M., Guengerich F.P., et al. In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. J Pharmacol Exp Ther 1996, 279:4-11.
52. Rodriguez C., Calle E.E., Miracle-McMahill H.L., Tatham L.M., Wingo P.A., Thun M.J., et al. Family history and risk of fatal prostate cancer. Epidemiology 1997, 8:653-659.